Biotech

On Thursday, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk A/S’ (NYSE:NVO) Wegovy pill, clearing the company's first daily oral weight-management treatment for adults with obesity or overweight conditions linked to weight-related health issues. The...

Takeda Pharmaceutical Company Limited (NYSE:TAK) on Thursday shared topline results for the Phase 3 comparing zasocitinib (TAK-279) to Bristol-Myers Squibb Co.’s (NYSE:BMY) Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque psoriasis (PsO). Head-To-Head Trial Meets Endpoints...

Johnson & Johnson (NYSE:JNJ) on Thursday presented detailed results from its Phase 2/3 ENERGY study showing that IMAAVY (nipocalimab-aahu) achieved a statistically significant, durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA). The rare blood disorder occurs...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported new clinical data showing that CASGEVY (exagamglogene autotemcel) delivered efficacy and safety outcomes in children ages 5 to 11 with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) The data were consistent...

Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic eye condition that primarily affects children. The eye care company said the move reflects its...

Humacyte Inc. (NASDAQ:HUMA) stock plunged Thursday despite reporting positive interim Phase 3 data for its acellular tissue-engineered vessel (ATEV), as investors focused on a heavily dilutive stock offering announced alongside the clinical update. On Wednesday, Humacyte released interim Phase 3...

Novartis AG (NYSE:NVS) said Thursday that the biomarker cohort of its Phase 1/2 FORTITUDE study evaluating investigational therapy del-brax met both its primary and key secondary endpoints in patients with facioscapulohumeral muscular dystrophy (FSHD), a rare neuromuscular disease. Trial Meets...

Sanofi SA (NASDAQ:SNY) on Wednesday announced that it will discontinue its Phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had not responded to standard treatments. CIDP is a rare, acquired autoimmune disorder of the...

Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) revenue growth and stock valuation is being driven by the adoption of Ziihera as a first-line (1L) treatment of HER2-positive (HER2+) metastatic gastroesophageal adenocarcinoma (GEA), according to BofA Securities. • Jazz Pharmaceuticals stock is...

Nexalin Technology Inc. (NASDAQ:NXL) on Wednesday reported clinical trial results in Brazil. The trial showed improvements in anxiety, depression, insomnia, and quality-of-life measures, supporting its drug-free neurostimulation approach. Anxiety Response Reached 77.8% Nexalin said an 8-week...

Incyte Corporation (NASDAQ:INCY) said Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront. The transaction will add late-stage candidate VGA039 to Incyte's hematology portfolio and could reach a total value of...

On Monday, Gilead Sciences Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda in previously untreated metastatic non-small cell lung cancer with high PD-L1 expression, following a Data Monitoring...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma. The clinical-stage biopharmaceutical company is focused on cell therapy for autoimmune diseases. The partnership aims to advance the development of...

AstraZeneca Plc (NASDAQ:AZN) is advancing its oral GLP-1 receptor agonist, elecoglipron, into an extensive Phase 3 development program after the drug delivered significant weight-loss and diabetes-control results in two Phase 2b studies. The findings, presented at the 2026 Scientific Sessions of...

Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday’s session as the biotechnology company announced an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its pivotal Phase 3 program for ATH434 in treating Multiple System Atrophy (MSA). The...